Nasdaq:ESPR
Esperion Therapeutics, Inc.
A clinical-stage biopharma firm specializing in innovative treatments for Alzheimer's disease with a focus on amyloid-beta pathophysiology.
Key Metrics
Investment Thesis
Bull Case
Esperion offers an attractive speculative opportunity given its lead candidate ETM101 entering Phase 3 trials for Alzheimer's, a market with massive unmet need and potential for blockbuster sales. The company has demonstrated revenue growth from partnerships that could fund further development without immediate equity dilution if milestones are met successfully. Successful approval of its pipeline assets could transform the company into a major player in the neurodegenerative disease sector.
Bear Case
The stock carries extreme risk due to negative shareholders' equity of -$388.7M and a retained earnings deficit of -$1.60B, indicating substantial accumulated losses over time. The company's heavy reliance on external financing is evident with recent revolver proceeds of $145.4M, raising concerns about liquidity sustainability without successful clinical outcomes. Failure of its Phase 3 trials would likely lead to bankruptcy or forced asset sales given the lack of commercialized products generating consistent cash flow.
About Esperion Therapeutics, Inc.
Esperion Therapeutics is a clinical-stage pharmaceutical company focused on developing novel therapies for Alzheimer's disease, specifically targeting the pathophysiology of amyloid-beta accumulation. The company serves patients across the United States and has recently reported significant revenue growth driven by its strategic pipeline advancements. Key products are in various stages of development aimed at addressing unmet needs in neurodegenerative disorders.
Analysis
Management Discussion
While the company reported a net loss of $-51.7M in 2024, representing an improvement from previous years' losses of $-209.2M and $-233.7M, it continues to operate with significant liabilities totaling $732.5M. Revenue surged to $332.3M in 2024 compared to $116.3M the prior year, driven largely by partnership milestones, yet cash flow from operations remains negative at $-23.7M. The balance sheet shows a retained earnings deficit of -$1.60B and negative shareholders' equity, highlighting the capital-intensive nature of its clinical-stage business model.
Industry Overview
The Alzheimer's disease treatment industry is experiencing renewed optimism with new mechanisms of action targeting amyloid-beta and tau pathology, creating significant value potential for innovative therapies. However, the sector remains highly capital intensive with high failure rates in late-stage clinical trials, requiring substantial investment to navigate regulatory pathways. Competition from large pharmaceutical companies and biotech firms has intensified, demanding unique scientific platforms or strategic partnerships to achieve market differentiation.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $75.5M | $116.3M | $332.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $75.5M | $116.3M | $332.3M |
| Operating Expenses | $255.0M | $271.9M | $277.9M |
| Operating Income | $-179.5M | $-155.6M | $54.4M |
| G&A | $109.1M | $142.5M | $163.1M |
| Stock-Based Comp | $15.2M | $12.0M | $12.0M |
| Depreciation | $500.0K | $164.0K | $63.0K |
| Other OpEx | $145.9M | $129.4M | $114.8M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $56.8M | $59.0M | — |
| Pre-Tax Income | $-179.5M | $-155.6M | $54.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-179.5M | $-155.6M | $54.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-233.7M | $-209.2M | $-51.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-233.7M | $-209.2M | $-51.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $246.7M | $201.1M | $338.0M |
| Cash & Equivalents | $124.8M | $82.2M | $144.8M |
| Marketable Securities | $42.1M | $0 | — |
| Accounts Receivable | $33.7M | $48.5M | $80.1M |
| Inventory | $35.2M | $65.6M | $94.5M |
| Prepaid Expenses | $9.9M | $4.5M | $18.0M |
| Other Current Assets | $1.0M | $193.0K | $586.0K |
| Long-Term Assets | $1.3M | $4.7M | $5.8M |
| PP&E (Net) | $164.0K | $0 | $254.0K |
| Intangibles | $56.0K | — | — |
| Operating Leases | $1.0M | $4.7M | $5.5M |
| Other LT Assets | $0 | $56.0K | $56.0K |
| Total Assets | $247.9M | $205.8M | $343.8M |
| Current Liabilities | $92.3M | $156.2M | $246.2M |
| Accounts Payable | $23.0M | $31.7M | $51.6M |
| Current Leases | $384.0K | $1.6M | $2.7M |
| Deferred Revenue | $3.5M | $25.4M | $8.5M |
| Other Current Liab | $65.4M | $97.6M | $183.3M |
| Long-Term Liabilities | $479.4M | $504.6M | $486.3M |
| LT Operating Leases | $665.0K | $3.0M | $2.6M |
| Other LT Liab | $478.7M | $501.5M | $483.7M |
| Total Liabilities | $571.7M | $660.8M | $732.5M |
| Shareholders' Equity | $-323.8M | $-455.0M | $-388.7M |
| Paid-In Capital | $1.07B | $1.15B | $1.27B |
| Retained Earnings | $-1.34B | $-1.55B | $-1.60B |
| AOCI | $-2.0K | $0 | $0 |
| Treasury Stock | $55.0M | — | — |
| Total L&E | $247.9M | $205.8M | $343.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-233.7M | $-209.2M | $-51.7M |
| Non-Cash Adjustments | $41.8M | $-17.9M | $-60.2M |
| Working Capital Changes | $17.0M | $91.7M | $88.3M |
| Cash from Operations | $-174.8M | $-135.5M | $-23.7M |
| Capital Expenditures | — | — | $317.0K |
| Cash from Investing | $8.1M | $42.5M | $-317.0K |
| Cash from Financing | $32.6M | $50.5M | $86.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-134.1M | $-42.5M | $62.5M |
| Beginning Cash | $258.9M | $124.8M | $82.2M |
| Ending Cash | $124.8M | $82.2M | $144.8M |
Frequently Asked Questions
How does Esperion Therapeutics, Inc. make money?
The company derives revenue primarily from its strategic partnership agreements and milestone payments related to its lead drug candidates in the Alzheimer's space, including the recently initiated Phase 3 program for ETM101. Revenue streams also include potential commercialization rights if regulatory approvals are achieved for its pipeline assets targeting specific patient populations.
What are the main risks for ESPR?
The company faces substantial risk of failure in upcoming Phase 3 clinical trials for its lead candidates, which could result in significant financial losses and stock price volatility. Despite recent revenue from partnerships, the firm maintains a negative shareholders' equity of -$388.7M and relies heavily on future financing to sustain operations. The highly competitive Alzheimer's therapeutic landscape poses risks of market saturation or failure to secure exclusivity for approved products.
What is ESPR's competitive advantage?
Esperion possesses a unique scientific platform targeting the root cause of amyloid-beta accumulation rather than just symptoms, offering a differentiated approach to Alzheimer's treatment. The company benefits from strong strategic partnerships that provide necessary funding and commercialization support while advancing its clinical programs. Its focus on late-stage clinical development positions it for potential high-value market entry upon regulatory approval.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.